When SGLT2i are assessed in T2D patients, these are less likely to have impaired CSF p-tau levels and altered t-tau/Aβ42 ratio, although the effects seem to be dependent on metabolic control [318]. Here, MAPT is linked to type 2 diabetes mellitus.